Publication:
Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the Turkish Oncology Group

Thumbnail Image

Organizational Units

Program

School / College / Institute

KUH (KOÇ UNIVERSITY HOSPITAL)

KU-Authors

KU Authors

Co-Authors

Unal, Caglar
Azizy, Abdulmunir
Karabulut, Senem
Tastekin, Didem
Akyildiz, Arif
Yasar, Serkan
Yalcin, Suayib
Coban, Eyup
Evrensel, Turkkan
Kalkan, Ziya

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.Results: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second-and =third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.Conclusions and Relevance: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.

Source

Publisher

Oxford Univ Press

Subject

Oncology

Citation

Has Part

Source

Oncologist

Book Series Title

Edition

DOI

10.1093/oncolo/oyad257

item.page.datauri

Link

Rights

Rights URL (CC Link)

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

3

Views

5

Downloads

View PlumX Details